Skip to main content
. 2021 Aug 18;12(2):907–923. doi: 10.1016/j.apsb.2021.08.016

Figure 5.

Figure 5

In vivo bio-distribution and anti-cancer activities of TFENs based on a subcutaneous xenograft breast tumor model. (A) In vivo bio-distribution of DiR-loaded TFENs in tumor, heart, liver, spleen, lung, and kidney at different time points (6, 12, 24, 48, and 72 h). (B) Relative body weight variations and (C) tumor volume variations over 9 days after the treatment of TFENs via i.v. injection and oral route. (D) Tumor weights on day 9. (E) Histological analysis of resected tumor sections from different treatment groups through H&E staining, TUNEL assay, and Ki-67 staining (scale bar = 100 μm). Each point represents the mean ± SEM (n = 6). ∗P < 0.05, ∗∗P < 0.01. ns, no significance.